Research programme: HIV integrase inhibitors - Merck
Alternative Names: L-870812; L-900564; MK-2048Latest Information Update: 24 Oct 2021
At a glance
- Originator Merck & Co
- Class Naphthyridines; Pyrimidinones
- Mechanism of Action HIV integrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 29 Aug 2011 No development reported - Preclinical for HIV infections in USA (PO)
- 10 Apr 2008 Interim pharmacokinetics and pharmacodynamics data from a preclinical study in HIV Infections presented at the the 235th American Chemical Society National Meeting (235th-ACS-2008)
- 14 Mar 2007 Data presented at the 14th Conference on Retroviruses and Opportunistic Infections (CROI-2007) added to the Viral Infections antimicrobial activity section